Table 2.
Overall and Location-specific Usage of Orthobiologics in the Treatment of Osteoarthritis by Respondents
| Osteoarthritis-specific Users | PRP-LR, 70.6% (n = 77) | PRP-LP, 76.1% (n = 83) | BMAC, 44.0% (n = 48) | AMP, 24.8% (n = 27) | Ad-MSC, 15.6% (n = 17) | UCD, 6.4% (n = 7) |
| Overall, 71.6% (n = 78) | ||||||
| Nonsurgical, 56.9% (n = 62) | 34.0% (n = 26) | 62.7% (n = 52) | 45.8% (n = 22) | 66.7% (n = 18) | 58.8% (n = 10) | 57.1% (n = 4) |
| Nonsurgical location | ||||||
| Shoulder | 19.2% | 50.0% | 41.0% | 55.6% | 80.0% | 75.0% |
| Elbow | 11.5% | 17.3% | 9.1% | 27.8% | 20.0% | 50.0% |
| Hip | 19.2% | 23.1% | 36.4% | 33.3% | 100.0% | 75.0% |
| Knee | 92.3% | 94.2% | 91.0% | 94.4% | 40.0% | 100.0% |
| Operative, 45.9% (n = 50) | 20.8% (n = 16) | 43.4% (n = 36) | 39.6% (n = 19) | 44.4% (n = 12) | 58.8% (n = 10) | 57.1% (n = 4) |
| Surgical location | ||||||
| Shoulder | 0% | 33.3% | 31.6% | 41.7% | 40.0% | 50.0% |
| Elbow | 0% | 11.1% | 12.5% | 16.7% | 10.0% | 25.0% |
| Hip | 6.3% | 22.2% | 31.6% | 33.3% | 10.0% | 50.0% |
| Knee | 93.7% | 97.2% | 94.7% | 100.0% | 100.0% | 100.0% |
Ad-MSC = adipose-derived mesenchymal stromal cells, AMP = amniotic membrane products, BMAC = bone marrow aspirate concentrate, PRP-LP = leukocyte-poor platelet-rich plasma, PRP-LR = leukocyte-rich platelet-rich plasma, UCD = umbilical cord–derived cells
Percentages in the top row and left-most column represent proportions with respect to all 109 users of any orthobiologics. Percentages throughout the rest of the table represent proportions with respect to the “n” value nearest vertically in the table. Specifically, percentages in the nonsurgical and surgical rows represent proportions with respect to all users of the orthobiologic indicated at the top of each column. Percentages in the rows below nonsurgical location and surgical location represent proportions with respect to all users of the column's specific orthobiologic in the indicated setting of nonsurgical or surgical.